PortalPublikationenUpdate Breast Cancer 2022 Part 2 - Advanced Stage Breast Can...

Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer

Standard

Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer. / Müller, Volkmar; Welslau, Manfred; Lüftner, Diana; Schütz, Florian; Stickeler, Elmar; Fasching, Peter A; Janni, Wolfgang; Thomssen, Christoph; Witzel, Isabell; Fehm, Tanja N; Belleville, Erik; Bader, Simon; Seitz, Katharina; Untch, Michael; Thill, Marc; Tesch, Hans; Ditsch, Nina; Lux, Michael P; Aktas, Bahriye; Banys-Paluchowski, Maggie; Schneeweiss, Andreas; Harbeck, Nadia; Würstlein, Rachel; Hartkopf, Andreas D; Kolberg, Hans-Christian; Wöckel, Achim.

in: GEBURTSH FRAUENHEILK, Jahrgang 82, Nr. 6, 06.2022, S. 590-600.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Müller, V, Welslau, M, Lüftner, D, Schütz, F, Stickeler, E, Fasching, PA, Janni, W, Thomssen, C, Witzel, I, Fehm, TN, Belleville, E, Bader, S, Seitz, K, Untch, M, Thill, M, Tesch, H, Ditsch, N, Lux, MP, Aktas, B, Banys-Paluchowski, M, Schneeweiss, A, Harbeck, N, Würstlein, R, Hartkopf, AD, Kolberg, H-C & Wöckel, A 2022, 'Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer', GEBURTSH FRAUENHEILK, Jg. 82, Nr. 6, S. 590-600. https://doi.org/10.1055/a-1811-6148

APA

Müller, V., Welslau, M., Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Thomssen, C., Witzel, I., Fehm, T. N., Belleville, E., Bader, S., Seitz, K., Untch, M., Thill, M., Tesch, H., Ditsch, N., Lux, M. P., Aktas, B., ... Wöckel, A. (2022). Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer. GEBURTSH FRAUENHEILK, 82(6), 590-600. https://doi.org/10.1055/a-1811-6148

Vancouver

Müller V, Welslau M, Lüftner D, Schütz F, Stickeler E, Fasching PA et al. Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer. GEBURTSH FRAUENHEILK. 2022 Jun;82(6):590-600. https://doi.org/10.1055/a-1811-6148

Bibtex

@article{13b8cc6f2fb146cb92ad2b0feea70c67,
title = "Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer",
abstract = "For patients with advanced breast cancer, several novel therapies have emerged in recent years, including CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, alpelisib, tucatinib and trastuzumab-deruxtecan, and sacituzumab-govitecan, which have transformed and expanded the therapeutic landscape for patients with advanced breast cancer. Some of these substances have now been approved for use in the early stages of the disease, or are expected to be approved in the near future, so the therapeutic landscape will change once again. Therefore, current scientific efforts are focused on the introduction of new substances and understanding their mechanisms of progression and efficacy. This review summarizes recent developments with reference to recent publications and conferences. Findings on the treatment of patients with HER2-positive breast cancer and brain metastases are presented, as are a number of studies looking at biomarkers in patients with HER2-negative, hormone receptor-positive breast cancer. In particular, the introduction of oral selective estrogen receptor degraders provides new opportunities to establish biomarker-based therapy. Molecular diagnostics is establishing itself as a diagnostic marker and parameter of progression.",
author = "Volkmar M{\"u}ller and Manfred Welslau and Diana L{\"u}ftner and Florian Sch{\"u}tz and Elmar Stickeler and Fasching, {Peter A} and Wolfgang Janni and Christoph Thomssen and Isabell Witzel and Fehm, {Tanja N} and Erik Belleville and Simon Bader and Katharina Seitz and Michael Untch and Marc Thill and Hans Tesch and Nina Ditsch and Lux, {Michael P} and Bahriye Aktas and Maggie Banys-Paluchowski and Andreas Schneeweiss and Nadia Harbeck and Rachel W{\"u}rstlein and Hartkopf, {Andreas D} and Hans-Christian Kolberg and Achim W{\"o}ckel",
note = "The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).",
year = "2022",
month = jun,
doi = "10.1055/a-1811-6148",
language = "English",
volume = "82",
pages = "590--600",
journal = "GEBURTSH FRAUENHEILK",
issn = "0016-5751",
publisher = "Georg Thieme Verlag KG",
number = "6",

}

RIS

TY - JOUR

T1 - Update Breast Cancer 2022 Part 2 - Advanced Stage Breast Cancer

AU - Müller, Volkmar

AU - Welslau, Manfred

AU - Lüftner, Diana

AU - Schütz, Florian

AU - Stickeler, Elmar

AU - Fasching, Peter A

AU - Janni, Wolfgang

AU - Thomssen, Christoph

AU - Witzel, Isabell

AU - Fehm, Tanja N

AU - Belleville, Erik

AU - Bader, Simon

AU - Seitz, Katharina

AU - Untch, Michael

AU - Thill, Marc

AU - Tesch, Hans

AU - Ditsch, Nina

AU - Lux, Michael P

AU - Aktas, Bahriye

AU - Banys-Paluchowski, Maggie

AU - Schneeweiss, Andreas

AU - Harbeck, Nadia

AU - Würstlein, Rachel

AU - Hartkopf, Andreas D

AU - Kolberg, Hans-Christian

AU - Wöckel, Achim

N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).

PY - 2022/6

Y1 - 2022/6

N2 - For patients with advanced breast cancer, several novel therapies have emerged in recent years, including CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, alpelisib, tucatinib and trastuzumab-deruxtecan, and sacituzumab-govitecan, which have transformed and expanded the therapeutic landscape for patients with advanced breast cancer. Some of these substances have now been approved for use in the early stages of the disease, or are expected to be approved in the near future, so the therapeutic landscape will change once again. Therefore, current scientific efforts are focused on the introduction of new substances and understanding their mechanisms of progression and efficacy. This review summarizes recent developments with reference to recent publications and conferences. Findings on the treatment of patients with HER2-positive breast cancer and brain metastases are presented, as are a number of studies looking at biomarkers in patients with HER2-negative, hormone receptor-positive breast cancer. In particular, the introduction of oral selective estrogen receptor degraders provides new opportunities to establish biomarker-based therapy. Molecular diagnostics is establishing itself as a diagnostic marker and parameter of progression.

AB - For patients with advanced breast cancer, several novel therapies have emerged in recent years, including CDK4/6 inhibitors, immune checkpoint inhibitors, PARP inhibitors, alpelisib, tucatinib and trastuzumab-deruxtecan, and sacituzumab-govitecan, which have transformed and expanded the therapeutic landscape for patients with advanced breast cancer. Some of these substances have now been approved for use in the early stages of the disease, or are expected to be approved in the near future, so the therapeutic landscape will change once again. Therefore, current scientific efforts are focused on the introduction of new substances and understanding their mechanisms of progression and efficacy. This review summarizes recent developments with reference to recent publications and conferences. Findings on the treatment of patients with HER2-positive breast cancer and brain metastases are presented, as are a number of studies looking at biomarkers in patients with HER2-negative, hormone receptor-positive breast cancer. In particular, the introduction of oral selective estrogen receptor degraders provides new opportunities to establish biomarker-based therapy. Molecular diagnostics is establishing itself as a diagnostic marker and parameter of progression.

U2 - 10.1055/a-1811-6148

DO - 10.1055/a-1811-6148

M3 - SCORING: Review article

C2 - 35903715

VL - 82

SP - 590

EP - 600

JO - GEBURTSH FRAUENHEILK

JF - GEBURTSH FRAUENHEILK

SN - 0016-5751

IS - 6

ER -